Leukemias

Farhad Ravandi MD and B. Douglas Smith MD review and share their expert perspectives on key findings in leukemia presented at the 2017 ASH annual meeting.

Share

Program Content

Activities

  • Inotuzumab + Bosutinib
    Interim Report: Inotuzumab Ozogamicin + Bosutinib in R/R Ph+ ALL or CML in Lymphoid Blast Phase
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

  • Midostaurin Maintenance
    Midostaurin Maintenance After Midostaurin Plus Chemotherapy in FLT3-Mutated AML: Post Hoc Analysis in RATIFY
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2017

  • EURO-SKI: TKI Cutoffs in CML
    EURO-SKI: Defining Cutoffs for Tyrosine Kinase Inhibitor Cessation in Patients With Chronic Myeloid Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

  • HOVON97: Azacitidine Maint
    Phase III HOVON97: Azacitidine Maintenance in Older Patients With AML and Refractory Anemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2017

  • RATIFY: <i>NPM1</i> and <i>FLT3</i>
    Prognostic Role of NPM1/FLT3-ITD Genotypes in AML: Analysis of the RATIFY Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

  • Gilteritinib in ND AML
    Gilteritinib With Induction and Consolidation Chemotherapy for Newly Diagnosed AML: Preliminary Phase I Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2017

  • Ivosidenib in AML
    Phase I Study: Ivosidenib (AG-120) in Mutant IDH1 Acute Myeloid Leukemia and Other Advanced Hematologic Malignancies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2017

  • mIDH Inhibition in AML
    Phase I Study: Ivosidenib or Enasidenib + Standard Induction Chemotherapy in Newly Diagnosed AML With IDH1/IDH2 Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

  • Nivolumab + IA in AML
    Phase II Study: Frontline Cytarabine and Idarubicin + Nivolumab in Newly Diagnosed AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2017

  • Venetoclax + LDAC in AML
    Phase I/II Study of Venetoclax + Low-Dose Cytarabine in Untreated, Elderly Patients With AML: Outcomes at 1 Year
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2017

  • CPX-351 in High-Risk AML
    CPX-351 in Patients With Newly Diagnosed AML at High Risk for Induction Mortality: Initial Phase II Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2017

  • Nilotinib + PegIFN in CP CML
    Phase III PETALs Interim Analysis: Nilotinib ± PegIFN alfa-2a in Patients With Newly Diagnosed Ph-Positive CP CML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2017

  • Ponatinib + Steroids in Ph+ ALL
    GIMEMA LAL1811: Phase II Study of Frontline Ponatinib + Steroids in Elderly or Unfit Patients With Ph+ ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2017

  • NGS for MRD in AML
    Prospective Molecular MRD Detection in AML by Next-Generation Sequencing
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology